title: Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study.
abstract: The prothrombin G20210A mutation is a common risk factor for thrombosis which increases the risk of deep vein thrombosis, stroke, and fetal loss. There are few publications of its clinical manifestations in children. Our objective was to determine the clinical manifestations of the prothrombin mutation in children. Via survey of pediatric hematologists, we collected data on children with thrombosis and the prothrombin mutation. Thirty-eight patients with a thrombotic event were identified as having the prothrombin mutation. Children with arterial thrombosis were younger, less than half had additional risk factors present at the time of the event, and had a high frequency of central nervous system thrombosis. Children with venous thrombosis were older, almost always had additional risk factors present, and had thrombosis occur most often in the extremities, although there were also a significant number of events in the central venous and cerebral circulation. There was a striking predilection for central nervous system events as 30% of all the events and 67% of the arterial events occurred there. In all, 14/38 children (37%) had central nervous system thrombosis. Unlike factor V Leiden and deficiencies of proteins C and S which cause venous thromboembolism, the prothrombin mutation in children is often associated with arterial thrombosis and with central nervous system events. In children with the prothrombin mutation and venous thrombosis, other risk factors are usually present. Therefore, children with arterial or venous thrombosis of any location should be evaluated for the presence of the prothrombin mutation.
authors.affiliation: Children's Hospital of Orange County, Orange, California 92868, USA. gyoung@choc.org
authors.forename: G
authors.initials: G
authors.lastname: Young
authors.forename: M
authors.initials: M
authors.lastname: Manco-Johnson
authors.forename: J C
authors.initials: JC
authors.lastname: Gill
authors.forename: D M
authors.initials: DM
authors.lastname: Dimichele
authors.forename: M D
authors.initials: MD
authors.lastname: Tarantino
authors.forename: T
authors.initials: T
authors.lastname: Abshire
authors.forename: D J
authors.initials: DJ
authors.lastname: Nugent
mesh_terms: D000293:Adolescent; D017677:Age Distribution; D001157:Arterial Occlusive Diseases / Q000453:epidemiology / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D005260:Female; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017354:Point Mutation; D011516:Prothrombin / Q000235:genetics*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D013927:Thrombosis / Q000453:epidemiology / Q000235:genetics*; D020246:Venous Thrombosis / Q000453:epidemiology / Q000235:genetics
chemical_list: D011516:Prothrombin